Abstract
Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Current Drug Safety
Title:Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis
Volume: 10 Issue: 2
Author(s): Raoudha Slim, Neila Fathallah, Amina Aounallah, Mehdi Ksiaa, Badreddine Sriha, Rafiaa Nouira and Chaker Ben Salem
Affiliation:
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Abstract: Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Export Options
About this article
Cite this article as:
Slim Raoudha, Fathallah Neila, Aounallah Amina, Ksiaa Mehdi, Sriha Badreddine, Nouira Rafiaa and Salem Ben Chaker, Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/1574886309666140827122735
DOI https://dx.doi.org/10.2174/1574886309666140827122735 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assay and Dermatokinetics of Tetrahydrocurcumin Lipidic Nanostructures Using Reverse Phase-high Performance Liquid Chromatography
Pharmaceutical Nanotechnology Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
Current Vascular Pharmacology Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Association of Variants in FCGR2A, PTPN2, and GM-CSF with Cerebral Cavernous Malformation: Potential Biomarkers for a Symptomatic Disease
Current Neurovascular Research Pediatric Eosinophilic Esophagitis: Epidemiology, Diagnosis and Treatment
Current Pediatric Reviews Subject Index to Volume 2
Current Drug Targets - Inflammation & Allergy Nitroxyl (HNO): A Possible Strategy for Fighting Cancer
Current Topics in Medicinal Chemistry First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dellAdulto) Multiple Myeloma Working Party Perspective
Current Drug Targets Reservoirs of HIV Replication After Successful Combined Antiretroviral Treatment
Current Medicinal Chemistry η3-Allylruthenium Complexes and Ruthenium-Catalysed Nucleophilic Substitution of Allylic Substrates
Current Organic Chemistry Granulocyte Apoptosis and Macrophage Clearance of Apoptotic Cells as Targets for Pharmacological Intervention in Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Use of Adenoviral Vectors for Genetic Manipulation and Analysis of Primitive Hematopoietic Cells
Current Gene Therapy Synaptic Activity-Regulated Wnt Signaling in Synaptic Plasticity, Glial Function and Chronic Pain
CNS & Neurological Disorders - Drug Targets Anti-Angiogenic Agents in Pancreatic Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology Immunogenicity Assessment of Therapeutic Proteins and Peptides
Current Pharmaceutical Biotechnology Approaches to the Management of Acute Kidney Injury in Children
Recent Patents on Biomarkers ACKNOWLEDGEMENTS TO REVIEWERS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued)